Latest news with #NasdaqHearingsPanel
Associated Press
29-07-2025
- Business
- Associated Press
Nasdaq Delisting Notice and Hearing Request
London, United Kingdom July 28, 2025 --( )-- Argo Blockchain plc ('Argo' or the 'Company') Argo Receives Nasdaq Delisting Notice and Intends to Request a Hearing As previously announced, on 16 January 2025, Argo Blockchain plc (LSE: ARB; Nasdaq: ARBK) received a letter from The Nasdaq Stock Market LLC Listing Qualifications Department ('Nasdaq') indicating that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) because the bid price of Argo's American Depositary Shares ('ADSs') closed below $1.00 per share for 30 consecutive business days. Argo announces today that it received a letter from Nasdaq dated 18 July 2025, indicating that Argo has not regained compliance with the minimum bid price requirement pursuant to the cure period provided by Nasdaq Listing Rule 5810(c)(3)(A) by the prescribed deadline of 15 July 2025, and that, as a result, Nasdaq has determined to delist Argo's ADSs from the Nasdaq Global Select Market. In accordance with the Nasdaq Listing Rules, Argo intends to request a hearing before a Nasdaq Hearings Panel. The hearing request will automatically stay any suspension or delisting action pending the conclusion of the hearings process and it is expected that the Company's securities will continue to trade on Nasdaq under its trading symbol: ARBK. There can be no assurance that Argo will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with all other applicable Nasdaq Listing Rules, or that Argo's hearing will be successful. If Argo's securities are suspended from trading on or delisted from Nasdaq, it could become more difficult to buy or sell Argo's ADSs or to obtain accurate quotations, and the price of Argo's ADSs could suffer a material decline. Further announcements will be made as appropriate. This announcement contains inside information. For further information please contact: Argo Blockchain Investor Relations [email protected] Tennyson Securities Corporate Broker Peter Krens +44 207 186 9030 Fortified Securities Joint Broker Guy Wheatley, CFA +44 7493 989014 [email protected] Tancredi Intelligent Communication UK & Europe Media Relations [email protected] About Argo: Argo Blockchain plc is a dual-listed (LSE: ARB; NASDAQ: ARBK) blockchain technology company focused on large-scale cryptocurrency mining. With a mining facility in Quebec and offices in the US, Canada, and the UK, Argo's global, sustainable operations are predominantly powered by renewable energy. In 2021, Argo became the first climate positive cryptocurrency mining company, and a signatory to the Crypto Climate Accord. For more information, visit This release contains information about Argo management's view of future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors and are subject to certain assumptions, risks, uncertainties and changes in circumstances. If Argo is unable to regain compliance with the Nasdaq minimum bid price requirement and its hearing is unsuccessful, its ADSs will be delisted from the Nasdaq Global Select Market. If the ADSs are delisted from the Nasdaq Global Select Market, they may trade on the over-the-counter market, which may be a less liquid market. In such case, your ability to trade, or obtain quotations of the market value of, the ADSs could be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices for the ADSs. Contact Information: Argo Blockchain plc Investor Relations +44 203 434 2330 Contact via Email Read the full story here: Nasdaq Delisting Notice and Hearing Request Press Release Distributed by
Business Insider
17-07-2025
- Business
- Business Insider
Graphjet Technology Stock (GTI) Rockets 80% on Listing Compliance Update
Graphjet Technology (GTI) stock soared on Wednesday after it provided investors with a business update. The graphite and graphene producer patent holder outlined its plans to regain compliance with Nasdaq listing requirements. This includes the filing of its Form 10-K yesterday, as well as a hearing with the Nasdaq Hearings Panel tomorrow. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. One key issue the company has to address is its stock price. Shares of GTI stock trade for 13 cents as of this writing, well below the $1 minimum bid price required to remain on the exchange. The company intends to address this with a reverse stock split that will boost the price of its shares. It will hold a shareholders' meeting on July 30, 2025, to vote on this matter. Graphjet Technology CEO Chris Lai said, 'We are confident that our plan to be address the non-compliances with the Nasdaq listing requirements can be implemented.' Graphjet Technology Stock Movement Today GTI stock was up 78.9% in pre-market trading on Wednesday, following a 3.84% rally yesterday. However, the shares have decreased 91.89% year to date and 98.51% over the past 12 months. Today's rally came with heavy trading, as some 262 million shares changed hands, compared to a three-month daily average of about 22.44 million units.
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. On April 23, 2025, Salarius was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius' common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. On March 26, 2025, Nasdaq notified the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on The Nasdaq Stock Market. On June 16, 2025, Salarius disclosed that the Nasdaq Hearings Panel had granted an extension contingent on Salarius achieving milestones that consist of regaining compliance with the Equity Standard by early July 2025, and regaining compliance with the Minimum Bid Price Requirement by early August 2025. On January 13, 2025, Salarius announced entry into a definitive merger agreement for a business combination with Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics. Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics. About the Planned Merger The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy's pipeline of peptide conjugate therapeutics engineered by its IMP 3 ACT platform, which allows for the rapid computational design and manufacturing of innovative peptide conjugate therapeutics. Decoy's product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications. In addition to advancing the development of Decoy's IMP 3 ACT platform, the combined company intends to incorporate Salarius' oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACS) drug candidate. The combined company will be led by Decoy's Co-founders, Chief Executive Officer Frederick 'Rick' Pierce and Chief Scientific Officer Barbara Hibner, by Decoy's Chief Business Officer Peter Marschel, Chief Technology Officer Mike Lipp, by acting Chief Medical Officer and Scientific Advisory Board Chair Shahin Gharakhanian, M.D. and by Salarius' Chief Financial Officer Mark Rosenblum. During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress with its other programs including a broad-acting antiviral against flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. Also during this time, data may be reported from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius' seclidemstat as a potential treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia in patients with limited treatment options. About Decoy Therapeutics, Inc. Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response. For more information, please visit About Salarius Pharmaceuticals Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius' product portfolio includes seclidemstat, the company's lead candidate, which is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company's IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit About the Proposed Transaction Definitive agreements were executed with unanimous approvals by the Boards of Directors of Salarius and Decoy. The closing consideration will consist primarily of nonvoting preferred stock of Salarius, and it is expected that following closing and a post-closing stockholder vote to approve the conversion of the preferred shares into common stock, Decoy investors would own approximately 92.4% of the outstanding shares of the merged company and Salarius stockholders would own approximately 7.6% of the outstanding shares, in each case exclusive of any shares issued in any financing, including the qualifying financing(s) necessary to consummate the merger transaction. For further details on the transaction and conditions for closing of the merger, please refer to the Form 8-Ks Salarius filed with the U.S. Securities and Exchange Commission (SEC) on each of January 13, 2025, March 8, 2025 and June 11, 2025 at Non-Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities in connection with the merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Salarius, Decoy, the proposed merger, Salarius' ability to regain compliance with the Nasdaq continued listing requirements and other matters, including without limitation, statements relating to plans and expectations relating to the business, scientific advisory board, products, including expected achievement of milestones for its lead asset and future prospects of Salarius, Decoy and the combined company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Salarius, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing are not satisfied, including uncertainties as to the timing of the consummation of the proposed merger; the ability of each of Salarius and Decoy to consummate the merger; risks and uncertainties related to Salarius' ability to regain compliance with the Nasdaq continued listing standards in the requirement timeframe; risks related to the combined company's ability to satisfy the initial listing standards in the required timeframe; Salarius may not receive any additional extensions from Nasdaq if Salarius is unable to regain compliance within the required timeframe; risks related to Salarius' ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing; risks that the combined company will not achieve the synergies expected from the proposed merger; risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP 3 ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Salarius' actual results may vary materially from those expected or projected.
Business Insider
12-07-2025
- Business
- Business Insider
Movano to request hearing from Nasdaq
Movano (MOVE) announced that it received a delisting determination from Nasdaq with respect to the $1.00 per share bid price requirement, as set forth in Listing Rule 5550(a)(2), and the late filing requirement, as set forth in Listing Rule 5250(c)(1), given the delay in filing its Form 10-Q for the quarter ended March 31. Accordingly, the company plans to timely submit a request for a hearing before a Nasdaq Hearings Panel. While the hearing request only stays suspension and delisting for 22 calendar days from the date of the Notice, the company intends to request an extended stay, concurrent with the filing of the hearing request through the conclusion of the hearings process and the expiration of any exception period granted by the panel following the hearing. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
31-05-2025
- Business
- Business Insider
FiEE reports Nasdaq to reinstate trading of company's common stock
FiEE (MINM) announced that following a hearing before the Nasdaq Hearings Panel on May 13 the Panel issued a decision on May 29, stating that Nasdaq will reinstate trading of the company's common stock on the Nasdaq Capital Market at the open of business on Monday, June 2, under the ticker symbol 'MINM'. Rafael Li, Chief Executive Officer of FiEE, commented, 'We are honored to announce the reinitiation of trading of our common stock on Nasdaq, a significant milestone that reflects our unwavering commitment to operational excellence and strategic growth. We extend our sincere gratitude to the Nasdaq team for their prompt review and approval of our request, affirming our compliance with all applicable criteria for continued listing on the Nasdaq Capital Market. FiEE, Inc. is currently undergoing a strategic transformation aimed at capitalizing on broader market opportunities. Central to this evolution is our integrated approach, where cyber-hardened IoT connectivity converges with AI-driven content creation and audience targeting. This synergy is designed to empower Key Opinion Leaders and brands to achieve accelerated growth and deeper audience engagement. Leveraging IoT-connectivity solutions, AI and big data analytics, we are capable of delivering intelligent, multimedia and multilingual content tailored to diverse audiences. Coupling with AI targeting analysis, we enhance audience targeting capabilities, ensuring effective content placement and personalized promotions. As we advance, our focus remains on continuous innovation and strategic initiatives that drive long-term growth and shareholder value.'
